DNA damage repair in ovarian cancer: unlocking the heterogeneity

Treatment for advanced ovarian cancer is rarely curative; three quarters of patients with advanced disease relapse and ultimately die with resistant disease. Improving patient outcomes will require the introduction of new treatments and better patient selection. Abrogations in the DNA damage respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Gee, Mary Ellen, Faraahi, Zahra, McCormick, Aiste, Edmondson, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011341/
https://www.ncbi.nlm.nih.gov/pubmed/29925418
http://dx.doi.org/10.1186/s13048-018-0424-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011341/
https://www.ncbi.nlm.nih.gov/pubmed/29925418
http://dx.doi.org/10.1186/s13048-018-0424-x

Ejemplares similares